Trajectories of injecting behavior in the Amsterdam Cohort Study among drug users

Trajectories of injecting behavior in the Amsterdam Cohort Study among drug users.

BACKGROUND Injecting frequency among people who inject drugs (IDU) can change along distinct trajectories, which can reflect on incidence of HIV and HCV infections. We aimed at assessing these patterns of longitudinal changes, their predictors and their association with the incidence of HIV and HCV. METHODS We analyzed data from the Amsterdam Cohort Study among Drug Users, selecting participa...

HIV risk behavior among injecting drug users in Amsterdam

Continuing injecting risk behaviour: results from the Amsterdam Cohort Study of drug users.

AIMS To give a detailed description of injection-related risk behaviours, and to estimate the relative importance of these behaviours with regard to HIV transmission. DESIGN The present study was part of the Amsterdam Cohort Study of drug users. SETTING In Amsterdam, a city with extensive preventive measures, large HIV-risk reductions have taken place, but no further decreases have occurred...

Long-term outcome of chronic drug use: the Amsterdam Cohort Study among Drug Users.

In the present study, mortality rates and prevalence of abstinence from illicit drugs among persons with a history of addiction to heroin, cocaine, and/or amphetamines were estimated along the drug-using career time scale. Follow-up data on drug use and vital status were analyzed for participants in the Amsterdam Cohort Study among Drug Users (n = 899; 1985-2002). Participants in the study were...

Frequent HCV reinfection and superinfection in a cohort of injecting drug users in Amsterdam.

BACKGROUND/AIMS This study investigates the occurrence of HCV reinfection and superinfection among HCV seroconverters participating in the Amsterdam Cohort Studies among drug users from 1985 through 2005. METHODS HCV seroconverters (n=59) were tested for HCV RNA at five different time points: the last visit before seroconversion (t=-1), the first visit after seroconversion (t=1), six months a...